Socrates Papapoulos
Overview
Explore the profile of Socrates Papapoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, et al.
Arch Osteoporos
. 2022 Jan;
17(1):20.
PMID: 35064844
Purpose: To examine the relationship between risk factors for fragility fracture (FF) and osteoporosis (OP) treatment gap in elderly women across Europe, and compare the prevalence of risk factors between...
2.
Papapoulos S, Bone H, Cosman F, Dempster D, McClung M, Nakamura T, et al.
J Bone Miner Res
. 2021 Mar;
36(7):1225-1234.
PMID: 33724542
We prospectively assessed, with predefined criteria, the location and rates of all femur fractures (hip, subtrochanteric/femoral shaft [ST/FS], including atypical [AFF] and distal fractures) in women at increased fracture risk...
3.
Rokidi S, Bravenboer N, Gamsjaeger S, Chavassieux P, Zwerina J, Paschalis E, et al.
Bone
. 2020 May;
137:115437.
PMID: 32473316
Bone Material Strength index (BMSi) measured by Impact Microindentation is generally lower in subjects with fragility fractures independently of BMD values. We recently reported that in humans, BMSi values are...
4.
Rokidi S, Bravenboer N, Gamsjaeger S, Misof B, Blouin S, Chavassieux P, et al.
Bone
. 2019 Oct;
131:115110.
PMID: 31655220
Impact microindentation (IMI) is a Reference Point Indentation technique measuring tissue-level properties of cortical bone in humans in vivo. The nature, however, of the properties that can affect bone strength...
5.
Watts N, Grbic J, Binkley N, Papapoulos S, Butler P, Yin X, et al.
J Clin Endocrinol Metab
. 2019 Feb;
104(6):2443-2452.
PMID: 30759221
Context: Antiresorptive therapy has been associated with osteonecrosis of the jaw (ONJ), an infrequent but potentially serious adverse event. Objective: To assess information on invasive oral procedures and events (OPEs)-dental...
6.
Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M, et al.
J Clin Endocrinol Metab
. 2018 May;
103(8):2949-2957.
PMID: 29800372
Purpose: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods:...
7.
Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments
Drake M, Fenske J, Blocki F, Zierold C, Appelman-Dijkstra N, Papapoulos S, et al.
Bone
. 2018 Mar;
111:36-43.
PMID: 29550267
Sclerostin is a 190 amino acid protein secreted primarily by osteocytes. It was initially identified due to mutations in the SOST gene associated with high bone mass phenotypes. Much recent...
8.
Bone H, Wagman R, Pannacciulli N, Papapoulos S
Lancet Diabetes Endocrinol
. 2017 Sep;
5(10):768-769.
PMID: 28938993
No abstract available.
9.
Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S, et al.
Lancet Diabetes Endocrinol
. 2017 May;
5(7):513-523.
PMID: 28546097
Background: Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of denosumab, which...
10.
Adachi J, Bone H, Daizadeh N, Dakin P, Papapoulos S, Hadji P, et al.
BMC Musculoskelet Disord
. 2017 Apr;
18(1):174.
PMID: 28449657
Background: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the...